EMA Authorised: Zelboraf (vemurafenib) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Zelboraf (vemurafenib) by Roche Registration GmbH for melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Roche Registration GmbH. Decision date: 19/06/2025